Literature DB >> 11956210

Tat acetyl-acceptor lysines are important for human immunodeficiency virus type-1 replication.

Vanessa Brès1, Rosemary Kiernan, Stéphane Emiliani, Monsef Benkirane.   

Abstract

The human immunodeficiency virus type-1 trans-activator Tat is a transcription factor that activates the HIV-1 promoter through binding to the trans-activation-responsive region (TAR) localized at the 5'-end of all viral transcripts. We and others have recently shown that Tat is directly acetylated at lysine 28, within the activation domain, and lysine 50, in the TAR RNA binding domain, by Tat-associated histone acetyltransferases p300, p300/CBP-associating factor, and hGCN5. Here, we show that mutation of acetyl-acceptor lysines to arginine or glutamine affects virus replication. Interestingly, mutation of lysine 28 and lysine 50 differentially affected Tat trans-activation of integrated versus nonintegrated long terminal repeat. Our results highlight the importance of lysine 28 and lysine 50 of Tat in virus replication and Tat-mediated trans-activation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11956210     DOI: 10.1074/jbc.M201895200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

1.  Selection of TAR RNA-binding chameleon peptides by using a retroviral replication system.

Authors:  Baode Xie; Valerie Calabro; Mark A Wainberg; Alan D Frankel
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

2.  The 5' UTR of HIV-1 full-length mRNA and the Tat viral protein modulate the programmed -1 ribosomal frameshift that generates HIV-1 enzymes.

Authors:  Johanie Charbonneau; Karine Gendron; Gerardo Ferbeyre; Léa Brakier-Gingras
Journal:  RNA       Date:  2012-01-27       Impact factor: 4.942

3.  Requirement for SWI/SNF chromatin-remodeling complex in Tat-mediated activation of the HIV-1 promoter.

Authors:  Céline Tréand; Isaure du Chéné; Vanessa Brès; Rosemary Kiernan; Richard Benarous; Monsef Benkirane; Stéphane Emiliani
Journal:  EMBO J       Date:  2006-04-06       Impact factor: 11.598

4.  HIV-1 Tat assembles a multifunctional transcription elongation complex and stably associates with the 7SK snRNP.

Authors:  Bijan Sobhian; Nadine Laguette; Ahmad Yatim; Mirai Nakamura; Yves Levy; Rosemary Kiernan; Monsef Benkirane
Journal:  Mol Cell       Date:  2010-05-14       Impact factor: 17.970

5.  Differential acetylation of Tat coordinates its interaction with the co-activators cyclin T1 and PCAF.

Authors:  Vanessa Brès; Hideaki Tagami; Jean-Marie Péloponèse; Erwan Loret; Kuan-Teh Jeang; Yoshihiro Nakatani; Stephane Emiliani; Monsef Benkirane; Rosemary E Kiernan
Journal:  EMBO J       Date:  2002-12-16       Impact factor: 11.598

6.  Acetylated Tat regulates human immunodeficiency virus type 1 splicing through its interaction with the splicing regulator p32.

Authors:  Reem Berro; Kylene Kehn; Cynthia de la Fuente; Anne Pumfery; Richard Adair; John Wade; Anamaris M Colberg-Poley; John Hiscott; Fatah Kashanchi
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

Review 7.  Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies.

Authors:  Laurence Colin; Carine Van Lint
Journal:  Retrovirology       Date:  2009-12-04       Impact factor: 4.602

8.  Controlling cellular P-TEFb activity by the HIV-1 transcriptional transactivator Tat.

Authors:  Lisa Muniz; Sylvain Egloff; Bettina Ughy; Beáta E Jády; Tamás Kiss
Journal:  PLoS Pathog       Date:  2010-10-14       Impact factor: 6.823

9.  In vitro nuclear interactome of the HIV-1 Tat protein.

Authors:  Virginie W Gautier; Lili Gu; Niaobh O'Donoghue; Stephen Pennington; Noreen Sheehy; William W Hall
Journal:  Retrovirology       Date:  2009-05-19       Impact factor: 4.602

10.  Comparative functional analysis of Jembrana disease virus Tat protein on lentivirus long terminal repeat promoters: evidence for flexibility at its N-terminus.

Authors:  Yang Su; Gang Deng; Yuanming Gai; Yue Li; Yang Gao; Jiansen Du; Yunqi Geng; Qimin Chen; Wentao Qiao
Journal:  Virol J       Date:  2009-10-28       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.